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Effect of Local Nasal Immunotherapy
on Nasal Blockage in Pollen-Induced
Allergic Rhinitis of Guinea Pigs
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Hiroshi Takenaka2 and Shigekatsu Kohno1
ABSTRACT
Background: As a non-injection route for immunotherapy, local nasal immunotherapy has been examined in
allergic rhinitis patients. However, it is unclear how the immunotherapy affects sneezing, biphasic nasal block-
age and nasal hyperresponsiveness. Thus, we evaluated the therapeutic effects of nasal immunotherapy on
the symptoms of guinea pig allergic rhinitis. Additionally, we also evaluated whether the immunotherapy re-
lieved pollen-induced allergic conjunctivitis.
Methods: Sensitized animals were repeatedly challenged by pollen inhalation once every week. After the 7th
challenge, the pollen extract was intranasally administered 6 times a week until the 30th challenge. Sneezing
frequency was counted after each of the challenges. As an indicator of nasal blockage, changes in specific air-
way resistance were measured. Nasal hyperresponsiveness was assessed by measuring leukotriene D4-
induced nasal blockage. Additionally, during the immunotherapy, we applied pollen onto the ocular surface to
induce the allergic conjunctivitis symptoms.
Results: At the 11th―30th challenges, the nasal immunotherapy showed inhibition or a tendency to inhibit the
biphasic nasal blockage although the inhibitions were variable at respective challenges. The development of
nasal hyperresponsiveness was markedly suppressed by the immunotherapy. Nevertheless, neither sneezing
nor antigen-specific IgE antibody production was substantially influenced by the immunotherapy. On the other
hand, the nasal immunotherapy did not affect the induction of allergic conjunctivitis symptoms.
Conclusions: Local nasal immunotherapy may be clinically useful for allergic nasal blockage associated with
nasal hyperresponsiveness. The mechanisms responsible for this effectiveness might not be related to IgE pro-
duction. Additionally, the effectiveness for nasal tissue was dissociated from that seen for the ocular tissue.
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INTRODUCTION
In order to relieve the symptoms of pollenosis, spe-
cific immunotherapies have been developed that use
subcutaneous administration of specific pollen anti-
gens.1 While subcutaneous immunotherapy has be-
come an established therapeutic modality, it is also
well known that subcutaneous injections of antigen
can potentially result in the occurrence of life-
threatening anaphylactic reactions.2 Thus, to avoid
such occurrences but still be able to provide specific
immunotherapy, oral immunotherapy has been inves-
tigated and clinically tested in patients with allergic
rhinitis.3 However, generally higher doses of the al-
lergen are needed when administered orally, which
in some cases can induce a cytotoxic effect on the di-
gestive tract.3
Another alternative non-injection route for immu-
notherapy is the use of local nasal immunotherapy.
This administration method has been examined in pa-
tients with allergic rhinitis.4-8 Local immunotherapy
has an advantage in that only a small amount of the
allergen is required as compared to that needed for
the oral immunotherapeutic methods.3 In most of the
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Fig. 1 Schedule for sensitization and chalenge with Japanese cedar polen, and intranasal instilations of the polen ex
tract for the intranasal immunotherapy in guinea pigs. S: Sensitization with the polen extract＋Al(OH)3 twice a day.
Week0 5 10 15 20 25 30
S
Challenge with the pollen once a week
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] [Time of challenge]
Intranasal immunotherapy (instillation of the pollen extract once a day, 6 times a week, 
           0.003 and 0.3 mg pollen-derived extract)
Measurement of nasal blockage and sneezing
Measurement of nasal hyperresponsiveness to LTD4
Checking whether nasal responses
are induced after the immunotherapy 
clinical examinations that have investigated local na-
sal immunotherapy, the therapy has been shown to
be effective in the induction of allergic nasal signs.4-8
However, due to the limitations of these previous
clinical studies, it is not clear as to how the immuno-
therapy is able to affect the various nasal allergic
symptoms, such as sneezing, biphasic nasal blockage
and nasal hyperresponsiveness to non-specific stim-
uli. Thus, there is a need to examine the effects on lo-
cal nasal mucosa using an experimental animal model
of allergic rhinitis that has symptoms similar to those
seen in clinical settings, and generate results that will
help to elucidate the mechanisms underlying the
therapeutic effect.
We have established a Japanese cedar pollen-
induced allergic rhinitis guinea pig model.9-12 In this
model, after a pollen inhalation challenge, there is im-
mediate sneezing and biphasically induced nasal
blockage.10 One of the characteristic features of ex-
perimental allergic rhinitis is that there is a markedly
increased nasal responsiveness to intranasally in-
stilled histamine or leukotriene (LT) D4.11,12 There-
fore, in the present study we tried to evaluate the ef-
fectiveness of local nasal immunotherapy in our ex-
perimental model. We also assessed whether nasal
immunotherapy affected allergic conjunctivitis in-
duced by dropping a pollen suspension into the eyes
of test subjects.
METHODS
ANIMALS
Male, 3-week-old Hartley guinea pigs were purchased
from Japan SLC (Hamamatsu, Japan). The animals
were housed in an air-conditioned room at a tempera-
ture of 23 ± 1℃ and 60 ± 10% humidity with the lights
on from 8:00 a.m. to 8:00 p.m. Animals were fed a
standard laboratory diet and given water ad libitum.
The first sensitization was started 2 weeks after the
arrival of the guinea pigs.
This animal study was approved by the Experimen-
tal Animal Research Committee at the Kyoto Pharma-
ceutical University.
ANTIGEN AND ADJUVANT
Japanese cedar (Cryptomeria japonica) pollen was
harvested in Gifu and Shiga prefectures (Japan) in
1998. Al (OH)3 gels were prepared with 0.25 N NaOH
and 0.25 N Al2(SO4)3, as has been previously de-
scribed.13
The cedar pollen extract used for the sensitization
was prepared as follows. The pollen was suspended
in PBS at 100 mgml followed by vigorous stirring at
4℃ for 48 hours. The suspension was then centri-
fuged and the supernatant collected. Protein concen-
tration in the supernatant was measured using the
method of Bensadoun and Weinstein.14 The extract
was combined with an Al(OH)3 suspension to achieve
a concentration of 100 μg protein100 mg Al (OH)3
ml.
The pollen extract used for the local nasal immuno-
therapy was prepared by centrifuging (4℃, 31,000 x
g, 30 minutes) the pollen suspension (100 mgml) af-
ter stirring for 48 hours. The supernatant collected
was then used for intranasal administration for the
immunotherapy.
SENSITIZATION AND CHALLENGE (Fig. 1)
Using a previously described method,10 guinea pigs
were sensitized by bilateral intranasal instillation of
the cedar pollen extract that was adsorbed onto the
Al(OH)3 gel at a concentration of 0.3 μg protein0.3
mg Al(OH)33 μleach nostril twice a day for 7 days.
To prevent rapid elimination of the antigen by ciliary
movement, the upper airway mucosal surface was
anesthetized through the use of a 2-min inhalation of
a mist of 4% lidocaine hydrochloride solution (MP
Biomedicals, Solon, OH, USA) that was generated by
an ultrasonic nebulizer (NE-U12, Omron, Osaka, Ja-
pan) prior to each sensitization session. The sensi-
tized animals were then intranasally challenged once
Local Immunotherapy for Pollenosis
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every week by inhalation of cedar pollen using a
handmade inhalation apparatus,9 which was designed
to allow for the quantitative inhalation of pollen. The
apparatus was loaded with 3 mg of pollen and then
positioned in one nostril of the conscious guinea pig
for 1 minute so that during spontaneous breathing,
the animal inhaled approximately 1.8 mgnostril of
the pollen. During the inhalation, the other nostril
was plugged with a finger, with the procedure then
repeated a second time for the other nostril. As a
negative control, a sensitized non-challenged group
was prepared for the experiments that assessed nasal
responsiveness to LTD4.
INTRANASAL ADMINISTRATION OF THE CE-
DAR POLLEN EXTRACT FOR IMMUNOTHERAPY
(Fig. 1)
Starting on the 1st day after the 7th challenge and un-
til 1 day before the 30th challenge, 6 times per week,
0.003 and 0.3 mg of pollen-derived extractanimal
was intranasally administered at a volume of 20 μl
animal. Control animals were treated with PBS in-
stead of the extract. There was no intranasal admini-
stration for immunotherapy carried out on the days of
the pollen inhalation challenge.
In order to check whether the instillations of the
pollen extract at the immunotherapy induced nasal
symptoms, time-course changes in sneezing fre-
quency and the specific airway resistance (sRaw)
were measured after an instillation of the extract on
days 15 and 86 after the start of immunotherapy.
COUNTING OF SNEEZING FREQUENCY
Sneezing frequency was counted during the first
hour after the pollen inhalation challenge.
MEASUREMENT OF SPECIFIC AIRWAY RESIS-
TANCE (sRaw)
sRaw was used as an indicator of the nasal blockage.
A two-chambered, double-flow plethysmograph sys-
tem along with a data analyzer Pulmos-I (MIPS,
Osaka, Japan) were used to measured the sRaw, in
accordance with the method of Pennock et al.15
MEASUREMENT OF NASAL RESPONSIVENESS
TO LTD4
Nasal responsiveness to intranasally instilled LTD4
was measured 2 days after the 16th and 30th pollen
inhalation challenges, as has been previously de-
scribed.12 At 20-minute intervals, increasing doses
(10 μleach nostril) of the LTD4 solution (0.01 and 0.1
μM) were bilaterally applied. sRaw was measured 10
minutes after each of the respective agonist doses.
MEASUREMENT OF Cry j 1- AND Cry j 2-
SPECIFIC IgE ANTIBODIES IN SERA
Cry j 1- and Cry j 2-specific IgE antibodies were deter-
mined by an enzyme-linked immunosorbent assay
(ELISA) kit16 (Guinea pig IgE ELISA MARUPI,
Dainippon Pharmaceutical Co., Osaka, Japan) using
blood samples collected 1 day before the 15th and
29th inhalation challenges. As this kit is designed for
the measurement of total IgE in the guinea pig, we
modified the method provided by the manufacturer in
order that we could measure Cry j 1- and Cry j 2-
specific IgEs, as has been previously described.17
Values for Cry j 1- and Cry j 2-specific IgE levels in
tested sera were expressed in arbitrary units relative
to the value of a pooled standard serum from the sen-
sitized challenged guinea pigs. The standard serum
was prepared by an i.p. injection of the pollen extract
adsorbed onto Al(OH)3 once every week for a total of
9 times in naïve guinea pigs. The sera were collected
2 weeks after the last sensitization, followed by a sub-
sequent pooling of all sera obtained. Cry j 1- and Cry j
2-specific IgE titers of the pooled serum were re-
garded as 1000 uml.
INDUCTION OF ALLERGIC CONJUNCTIVITIS
On the days prior to the 26th through the 28th inhala-
tion challenges, animals were challenged by dropping
a pollen suspension (2 mg pollen10 μleye) in each
eye, as has been previously reported.18,19 The magni-
tude of conjunctival edema and redness was judged
macroscopically and expressed as a conjunctivitis in-
tensity score (CIS) according to an arbitrary 5-point
graded scale, from 0 to 4 (0, no symptoms; 1, light; 2,
mild; 3, moderate; 4, severe).20
Scratching frequencies at 0―0.5 hours after the re-
spective 1st―3rd ophthalmic challenges were
counted. The scratch response was defined as an un-
interrupted cluster of rapid hindlimb movements that
were precisely directed to the ocular surface.
Ophthalmic lavage fluid was collected before and
0.5 hours after the 3rd challenge, with the amount of
albumin measured by an enzyme-linked immuno-
sorbent assay in accordance with the method of
Gawin et al.21 In brief, 10 μl of sterile physiologic sa-
line was applied to the eye using a micropipette, fol-
lowed by two or three forced blinks, with the fluid
then subsequently collected. The lavage was re-
peated 5 times in each eye. Once lavage fluids were
obtained from both eyes, the collected fluids were
then combined. Following the centrifugation of the
fluid, the supernatant was used for the measurement
of albumin.
STATISTICAL ANALYSES
Statistical analysis was performed by one-way analy-
sis of variance. If a significant difference was de-
tected, the individual group difference was deter-
mined by Bonferroni’s multiple test. A probability
value (P) < 0.05 was considered to be statistically sig-
nificant.
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Fig. 2 (A) Time-course change in specific airway resistance (sRaw) after the 7th inhalation chalenge with Japa-
nese cedar polen in sensitized guinea pigs. Based on the results at the 7th chalenge, 22 animals were divided 
into 3 groups that consisted of control and nasal immunotherapy groups that were treated with either 0.003 or 0.3 
mg polen-derived extract. Each point represents the mean ± S.E. of 22 animals. (B, C, D and E) Efect of nasal 
immunotherapy on early (EPR) and late phase response (LPR) of the biphasic nasal blockage induced by the 9th 
(B), 11th (C), 16th (D) and 30th (E) inhalation chalenges. One day after the 7th chalenge and continuing until the 
30th chalenge, 0.003 or 0.3 mg polen-derived extract was intranasaly administered 6 times a week. EPR and 
LPR are expressed as the area under the response curve (AUC) for the change in the specific airway resistance 
(sRaw) at 0―2 hours and 3―6 hours after the chalenges, respectively. Each column represents the mean ± S.E. 
of 7 or 8 animals. ＊p＜0.05 vs. control.
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RESULTS
EFFECT ON THE BIPHASIC NASAL BLOCKAGE
The 7th pollen inhalation challenge induced biphasic
nasal blockage (Fig. 2A), as has been previously re-
ported.10 Starting on the 1st day after the 7th chal-
lenge, the pollen extract was intranasally adminis-
tered 6 times a week. Figure 2B―E show the effect of
the local intranasal immunotherapy on the biphasic
nasal blockage for the 9th―30th inhalation challenges.
Early (EPR) and late phase responses (LPR) are ex-
pressed as the area under the response curve (AUC)
for the changes in sRaw at 0―2 hours and 3―6 hours
after the challenge, respectively. The nasal immuno-
therapy significantly inhibited both the EPR and LPR
at the 11th challenge (Fig. 2C). The tendency to in-
hibit the nasal blockage was observed at the 16th and
30th challenges, whereas the inhibitions were vari-
able, and not statistically significant (Fig. 2D, E).
EFFECTS ON SNEEZING
As previously reported,10 induction of sneezing oc-
curred within 1 hour after the respective pollen inha-
lation challenges, with sneezing frequencies of 10―20
timeshour. In contrast to the effects seen for the na-
sal blockage, the nasal immunotherapy did not sub-
stantially affect the frequency of sneezing that was in-
duced at the 9th―30th inhalation challenges (Fig. 3A―
D).
EFFECT ON THE DEVELOPMENT OF NASAL HY-
PERRESPONSIVENESS TO LTD4
Consistent with our previous findings,12 nasal respon-
siveness to LTD4 in the control group was markedly
Local Immunotherapy for Pollenosis
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Fig. 3 Efect of the nasal immunotherapy on the occurence of sneezing induced by the 9th (A), 11th 
(B), 16th (C) and 30th (D) inhalation chalenges with Japanese cedar polen in sensitized guinea pigs. As 
described in Fig. 1, extract derived from 0.003 or 0.3 mg polen was intranasaly administered. During the 
first hour after each chalenge, sneezing frequency was counted. Each column represents the mean ± 
S.E. of 7 or 8 animals.
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higher as compared with the sensitized non-
challenged guinea pig 2 days after the 16th and 30th
challenges (Fig. 4A, B). The development of nasal hy-
perresponsiveness after the challenges was almost
completely suppressed by the local nasal immuno-
therapy (Fig. 4A, B).
LACK OF INDUCTION OF NASAL SYMPTOMS
AFTER INTRANASAL INSTILLATION OF THE EX-
TRACT DURING IMMUNOTHERAPY
The effect of instillation of the extract during immu-
notherapy on induction of sneezing and nasal block-
age was assessed on days 15 and 86 after the start of
the immunotherapy. As shown in Table 1, 2, neither
nasal blockage at 1 and 4 hours after the instillation
nor sneezing within 1 hour was induced in 0.003 and
0.3 mg pollen-derived extract-treated groups.
INFLUENCE ON Cry j 1-AND Cry j 2-SPECIFIC
IgE PRODUCTION
Large amounts of both Cry j 1- and Cry j 2-specific
IgEs were detected in the sera at the 15th and 29th
inhalation challenges. Local nasal immunotherapy
had no effect on the production of IgE (Fig. 5A, B).
EFFECT ON POLLEN-INDUCED ALLERGIC CON-
JUNCTIVITIS
We also assessed whether local nasal immunother-
apy suppressed pollen-induced allergic conjunctivitis.
There was an apparent increase in the CIS even at
the 1st ophthalmic challenge with the pollen, with the
increase peaking at 0.5 hours. The scratching fre-
quency was also increased within 1 hour after the 1st
challenge. Both responses tended to be intensified at
the subsequent 2nd and 3rd challenges. However,
the nasal immunotherapy did not affect the induction
of the allergic conjunctivitis symptoms (Fig. 6A―F).
The amount of albumin in the ophthalmic lavage
fluid, which is an indicator of plasma extravasation,
was increased after the 3rd pollen challenge in the
eye. This increase in the albumin amount was not af-
fected by the nasal immunotherapy (Fig. 6G).
DISCUSSION
In the present study, therapeutic effects of nasal im-
munotherapy on the induction of allergic rhinitis
symptoms were evaluated in guinea pigs. Results in-
dicated that biphasic nasal blockage, which consists
of both EPR and LPR, was suppressed by nasal im-
munotherapy at the 11th―30th challenges, although
the influences were variable at respective challenges
and not apparent. Nasal responsiveness to intranasal
application of LTD4 was markedly increased in the
control animals at the 16th and 30th challenges. Inter-
estingly, the development of nasal hyperresponsive-
ness was completely inhibited by the immunother-
apy. Nevertheless, neither sneezing nor Cry j 1- and
Cry j 2-specific IgE production was influenced by the
therapy. On the other hand, after an intranasal ad-
ministration of 0.003 and 0.3 mg pollen-derived ex-
tract, there were no nasal symptoms in the sensitized
guinea pigs, as shown by the sRaw and sneezing fre-
Nabe T et al.
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Fig. 4 Efect of the nasal immunotherapy on the increase of nasal responsiveness to leukotriene 
(LT) D4 after the 16th (A) and 30th (B) inhalation chalenges with Japanese cedar polen in sensi-
tized guinea pigs. Extract derived from 0.003 or 0.3 mg polen was intranasaly administered as de-
scribed in Fig. 1. The nasal responsiveness to intranasal instilation of 0.01 and 1 μM LTD4 was 
assessed 2 days after the chalenges. Each point represents the mean ± S.E. of 7 or 8 animals. 
＊p＜0.05, ＊＊p＜0.01 and ＊＊＊p＜0.001 vs. control, †p＜0.05, ††p＜0.01 and †††p＜0.001 
vs. sensitized-non-chalenged group.
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Table 1 Lack of induction of nasal blockage after intranasal instilation of the polen extract for the immunotherapy
Changes in sRaw at 4 hours
[cmH2Oxml/(ml/s)]
Changes in sRaw at 1 hour
[cmH2Oxml/(ml/s)]Day
0.3 mg0.003 mgControl0.3 mg0.003 mgControl
0.15 ± 0.110.14 ± 0.150.23 ± 0.150.24 ± 0.100.30 ± 0.140.19 ± 0.1215
－0.01 ± 0.16－0.02 ± 0.140.03 ± 0.12－0.04 ± 0.150.06 ± 0.140.05 ± 0.0986
Extract derived from 0.003 or 0.3 mg polen was intranasaly administered as described in Fig. 1. Specific airway resistance (sRaw) 
was measured before, and 1 and 4 hours after the intranasal instilation of the extract on days 15 and 86 after the start of the 
immunotherapy. Each value represents the mean ± S.E. of 8 animals.
quency measurements. Thus, the effects of the nasal
immunotherapy may not be due to a decreased ana-
phylactic reaction that had been influenced by re-
peated antigen-antibody reactions at the nasal mu-
cosa.
The present results are essentially similar to our
previous study that examined the therapeutic effect
of oral immunotherapy in this experimental allergic
rhinitis model.17 In our oral immunotherapy study, 1
mg pollen-derived extract was orally administered un-
til the 30th challenge and was found to be effective in
biphasic nasal blockage and in the development of na-
sal hyperresponsiveness, although no effects were
noted on IgE production or on the occurrence of
sneezing.17 The magnitudes of the inhibition in the
development of the nasal hyperresponsiveness by the
nasal immunotherapy when using 0.003 and 0.3 mg
pollen-induced extract in the present study were al-
most equipotent to that seen in our previous oral im-
munotherapy study that used a 1 mg pollen-derived
extract.17 Although we have not examined the dose-
dependent effect of the oral immunotherapy, local na-
sal immunotherapy is effective at relatively low doses
of antigen, similar to that which has been reported in
clinical trials.3
In most local nasal immunotherapy clinical trials
for allergic rhinitis, nasal immunotherapy effectively
relieved the symptoms of allergic rhinitis, whereas
allergen-specific IgE production was not inhibited.4-8
Our present results are consistent with these clinical
Local Immunotherapy for Pollenosis
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Fig. 5 Efect of the nasal immunotherapy on the production of Cry j 1- (A) 
and Cry j 2- (B) specific IgEs at the 15th and 29th inhalation chalenges with 
Japanese cedar polen in sensitized guinea pigs. Extract derived from 0.003 or 
0.3 mg polen was intranasaly administered as described in Fig. 1. Sera were 
drawn 1 day before each chalenge. Each point represents the mean ± S.E. of 
7 or 8 animals.
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Table 2 Lack of induction of sneezing after intranasal in
stilation of the polen extract for the immunotherapy
Sneezing frequency (times/hour)
Day
0.3 mg0.003 mgControl
0.5 ± 0.30.4 ± 0.30.3 ± 0.215
0.8 ± 0.20.5 ± 0.30.8 ± 0.486
Extract derived from 0.003 or 0.3 mg polen was intranasaly 
administered as described in Fig. 1. Sneezing frequency was 
counted 0―1 hour after the intranasal instilation of the extract 
on days 15 and 86 after the start of the immunotherapy. Each 
value represents the mean ± S.E. of 8 animals.
findings.4-8 We have also previously reported that the
sneezing which was induced within 1 hour after chal-
lenge was almost completely suppressed by treat-
ment with anti-histaminics.22 This indicates that the
histamine that is released from the mast cells imme-
diately after the pollen inhalation plays a major role in
the occurrence of sneezing. Nevertheless, local nasal
immunotherapy inhibited neither the induction of
sneezing nor the increase of Cry j 1- and Cry j 2-
specific IgE levels. These findings are similar to the
results from our previous experiment that assessed
the effects of oral immunotherapy,17 and indicate that
nasal immunotherapy has no inhibitory effect on the
IgE-mediated mast cell activation at the nasal mu-
cosa.
However, presently there are no clear mechanisms
that can explain the effectiveness of the local nasal
immunotherapy on the development of nasal hyperre-
sponsiveness other than by inhibition of IgE produc-
tion and mast cell activation. However, the effective-
ness of the nasal immunotherapy was similar to the
results we obtained for the oral immunotherapy in
our previous study.17 Thus, it can be speculated that
even though the treatments for the intranasally and
orally applied allergens were different in the nasal-
and gut-associated lymphoid tissues, respectively, hy-
poresponsiveness to the allergen may be required for
both of these immunotherapy cases. Because recog-
nition of allergen by a specific IgE may not be af-
fected by the immunotherapy described above, it can
be speculated that antigen recognition by antigen-
presenting cells may be decreased, thus leading to
suppression of the nasal hyperresponsiveness. Fur-
ther detailed analyses need to be conducted in order
to elucidate these mechanisms.
On the other hand, the pollen-induced allergic con-
junctivitis was not affected by the nasal immunother-
apy even though there was sustained effectiveness in
the nasal tissue. The dissociation of the effectiveness
of the nasal immunotherapy between the nasal and
conjunctivitis tissues has also been reported in a pre-
vious clinical examination.7 It may well be that the na-
sal immunotherapy is effective only on the local or-
Nabe T et al.
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Fig. 6 Efect of the nasal immunotherapy on the Japanese polen-induced alergic con-
junctivitis in the sensitized guinea pigs. Extract derived from 0.003 or 0.3 mg polen was in-
tranasaly administered as described in Fig. 1. During the nasal immunotherapy (1 day 
before the 26th, 27th and 28th chalenges), animals were chalenged by dropping a polen 
suspension in each eye for a total of 3 times. (A, B and C) The magnitude of conjunctival 
edema and redness were macroscopicaly judged at 0―5 hours after the respective 1st―
3rd ophthalmic chalenges, and expressed as the conjunctivitis intensity score (CIS). (D, E 
and F) Scratching frequencies at 0―0.5 hours after the respective 1st―3rd chalenges 
were counted. (G) Albumin amounts in the ophthalmic lavage fluid that was colected be-
fore and 0.5 hour after the 3rd chalenge were measured by an enzyme-linked immuno-
sorbent assay. Each point or column represents the mean ± S.E. of 7 or 8 animals.
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gans, which are controlled by the nasal-associated
lymphoid tissue. However, in one of our previous
studies, oral immunotherapy, which may affect the
systemic immune system, was also found to be effec-
tive for nasal allergic symptoms even though it did
not have any effect on the conjunctival allergies (un-
published data). Thus, the immunological induction
mechanisms underlying the nasal blockage and hy-
perresponsiveness might be largely different from
those in allergic conjunctivitis. We have previously re-
ported that scratching incidence, increases in CIS,
and albumin leakage are all immediate allergic re-
sponses that peak at around 30 minutes after a pollen
challenge.18,19,23 These findings suggest that these re-
sponses are part of an IgE-dependent allergy, much
like the case of sneezing that is seen in the allergic
Local Immunotherapy for Pollenosis
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rhinitis model. These results also provide further sup-
port for the rationale that we can exclude the effects
on IgE-mediated mast cell activation as being a part
of the mechanism of this immunotherapy.
In conclusion, there was effective suppression of
both the biphasic nasal blockage and the develop-
ment of nasal hyperresponsiveness induced by the
subsequent pollen inhalation challenges in sensitized
guinea pigs undergoing intranasal administration of
pollen extract 6 times a week, although there was no
suppression of the sneezing. This inhibition was not
related to serum antigen-specific IgE levels. The ef-
fectiveness of this local nasal immunotherapy might
be due to a nasal hyporesponsiveness mechanism to
the specific allergen.
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